Published in 2021

BACKGROUND: Cross-sectional studies indicate that parental stress may be a barrier for healthy dietary behaviours among children. However, there is a lack of evidence from longitudinal studies on the association between parental stress and changes in dietary intake among toddlers. The aim of this study was to examine the association between parental stress and changes in dietary intake and quality among preschool children susceptible to obesity.

METHODS: In the Healthy Start study, parents to 250 preschool children had completed a modified version of the Parental Stress Index and assessed the dietary intake of their children at baseline and after 15 months of follow up. The association between parental stress and changes in dietary intake and quality was examined using multiple linear regression analyses with adjustment for potential confounders. We tested for potential effect modification by group allocation and sex.

RESULTS: There were no significant associations between parental stress and subsequent changes in child total energy intake, intake of macronutrients or intake of fruit, vegetables, sugar sweetened beverages, fish or starch, or dietary quality.

CONCLUSION: This study provides no evidence to support an association between parental stress and subsequent change in dietary intake and quality of their children.

TRIAL REGISTRATION: ClinicalTrials.gov, Trial number: NCT01583335, Registered: 31 March 2012, retrospectively registered.

Originalsprog Engelsk
Artikelnummer 3590
Tidsskrift International Journal of Environmental Research and Public Health
Vol/bind 18
Udgave nummer 7
ISSN 1661-7827
DOI
Status Udgivet - apr. 2021

Awareness and Expectations Surrounding Family Planning and Pregnancy Among Danish Patients with Chronic Inflammatory Disease of the Skin or Joints: Results from an Online Survey

Johansen, C. B., Laurberg, T. B., Egeberg, A., Jensen, U. F. A., Hansen, A. L., Skov, L., Kristensen, L. E., Thomsen, S. F. & Schreiber, K., 14 aug. 2021, I: Rheumatology and Therapy. 8, 3, s. 1419-1433 15 s.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Background: Patients with chronic inflammatory diseases (CIDs) may encounter challenges in their family planning journey. Here, we report on the access to family planning and pregnancy (FPP) information and the concerns among patients in Denmark with CIDs. Methods: Patients aged 18–50 years with CIDs participated in an online survey. Patients were recruited through patient advocacy groups and were asked to report information on their diagnosis, concerns related to FPP and perceptions of access to FPP information. Descriptive statistics were applied. Results: Of the eligible respondents, 368 had rheumatological diagnoses (rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis or axial spondyloarthritis; mean age 40 years; 83% women, 17% men) and 95 had dermatological diagnoses (psoriasis or psoriatic arthritis; mean age 38 years; 67% women, 33% men). Approximately 70% of all patients reported seeking FPP information from patient advocacy groups; 57% of both cohorts used the internet as information sources; and 73% and 42% of rheumatological and dermatological cohorts used their hospital and specialist doctor, respectively. Despite this, 58% and 67% of patients with rheumatological and dermatological diagnoses reported limited or no access to FPP information, with > 70% of dermatological patients of early/mid-reproductive age reporting a lack of access to this information. Overall, 68% of patients with rheumatological and 73% with dermatological diagnoses had biological children, amongst whom 24% and 18%, respectively, indicated their disease affected the number of children they ultimately decided to have. The most frequent FPP concerns among patients who did not want any/more biological children were disease worsening, heredity and taking care of the child. Conclusions: Despite awareness of available sources of FPP information, patients expressed experiencing a feeling of limited access to information and having concerns that affect key decisions regarding FPP. The results of this survey highlight a need for improved and more standardised FPP information for patients with CIDs in Denmark.

Originalsprog Engelsk
Tidsskrift Rheumatology and Therapy
Vol/bind 8
Udgave nummer 3
Sider (fra-til) 1419-1433
Antal sider 15
ISSN 2198-6576
DOI
Status Udgivet - 14 aug. 2021

Bibliografisk note

Funding Information:
The authors also acknowledge Vanessa Omnou, MSc, and Beverley Wilson, PhD, Costello Medical, UK, for medical writing and editorial assistance based on the authors’ input and direction. This study was funded by UCB Pharma in accordance with Good Publication Practice (GPP3) guidelines ( http://www.ismpp.org/gpp3 ).

Funding Information:
The authors thank the participants, the patient advocacy groups (The Arthritis Association [Gigtforeningen], The Association for Spinal Arthritis and Bechterew's Disease [Foreningen for Rygs?jlegigt og Morbus Bechterew] and The Psoriasis Association [Psoriasisforeningen]), the investigators and their teams who took part in this study. Survey implementation and data collection was managed by Incentive Denmark. This study and Rapid Service Fee was funded by UCB Pharma. The authors also acknowledge Vanessa Omnou, MSc, and Beverley Wilson, PhD, Costello Medical, UK, for medical writing and editorial assistance based on the authors? input and direction. This study was funded by UCB Pharma in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3). All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. Substantial contributions to study conception and design: C?cilie B Johansen, Trine B Laurberg, Alexander Egeberg, Ulla-Fie A Jensen, Asbj?rn L Hansen, Lone Skov, Lars E Kristensen, Simon F Thomsen and Karen Schreiberf. Substantial contributions to analysis and interpretation of the data: C?cilie B Johansen, Trine B Laurberg, Alexander Egeberg, Ulla-Fie A Jensen, Asbj?rn L Hansen, Lone Skov, Lars E Kristensen, Simon F Thomsen and Karen Schreiberf. Drafting the article or revising it critically for important intellectual content: C?cilie B Johansen, Trine B Laurberg, Alexander Egeberg, Ulla-Fie A Jensen, Asbj?rn L Hansen, Lone Skov, Lars E Kristensen, Simon F Thomsen and Karen Schreiberf. Final approval of the version of the article to be published: C?cilie B Johansen, Trine B Laurberg, Alexander Egeberg, Ulla-Fie A Jensen, Asbj?rn L Hansen, Lone Skov, Lars E Kristensen, Simon F Thomsen and Karen Schreiberf. An abstract summarising data from this manuscript was submitted to, and accepted for poster presentation at the European Alliance of Associations for Rheumatology (EULAR) 2020 Virtual Congress (from 3 June 2020; online): Schreiber K, Johansen C, Jensen UF, et al. PARE0024 Awareness about family planning and pregnancy expectation among patients with chronic inflammatory disease of the skin or joints (Annals of the Rheumatic Diseases 2020;79:1297?1298). C?cilie B Johansen: Advisory Boards for UCB Pharma; honoraria as consultant and/or speaker for Galderma, Estee Lauder Companies L'Or?al. Trine B Laurberg: Consultant and/or Advisory Boards for AbbVie and UCB Pharma. Karen Schreiberf: Consultant and/or Advisory Boards for UCB Pharma. Alexander Egeberg: Research funding from AbbVie, Bristol-Myers Squibb, the Danish National Psoriasis Foundation, Eli Lilly, Janssen Pharmaceuticals, the Royal Hofbundtmager Aage Bang Foundation, the Simon Spies Foundation, Novartis and Pfizer; honoraria as consultant and/or speaker from AbbVie, Almirall, Bristol-Myers Squibb, Dermavant, Eli Lilly, Janssen Pharmaceuticals, Galapagos NV, Galderma, LEO Pharma, Mylan, Novartis, Pfizer, Samsung Bioepis Co. Ltd., Sun Pharmaceuticals and UCB Pharma. Ulla-Fie A Jensen: Employee of UCB Pharma. Asbj?rn L Hansen: Former employee of UCB Pharma. Lone Skov: Speaker for AbbVie, Sanofi, Eli Lilly, LEO Pharma and Novartis; consultant and/or Advisory Boards for AbbVie, Almirall, Eli Lilly, Janssen Pharmaceuticals, LEO Pharma, Novartis, UCB Pharma, BMS and Sanofi; research and educational grants from AbbVie, Janssen Pharmaceuticals, LEO Pharma, Novartis, BMS and Sanofi. Lars E Kristensen: Consultant and/or Advisory Boards and/or speaker for AbbVie, Amgen, Biogen, Bristol-Myers Squibb, Eli Lilly, Gilead, Janssen Pharmaceuticals, MSD, Novartis, Pfizer, Sanofi and UCB Pharma. Simon F Thomsen: Consultant and/or Advisory Boards for AbbVie, Almirall, Celgene, Eli Lilly, Janssen Pharmaceuticals, LEO Pharma, Novartis, Pfizer, Roche and Sanofi; speaker for AbbVie, Eli Lilly, LEO Pharma, Novartis, Sanofi and UCB Pharma; research support from Abbvie, LEO Pharma, Janssen Pharmaceuticals, Novartis, Sanofi and UCB Pharma. Ethics approval was not required for this study. Under Danish legislation, questionnaire survey projects not involving human biological material are exempt from the obligation to notify the scientific ethics committee (Section 14 (2) of the Committee Act). Respondents were provided information on the conduct of the survey and had to provide consent before participating. Respondents were informed that the knowledge collected in the survey would be published and had to provide consent before participating. Data from non-clinical studies is outside of UCB?s data-sharing policy.

Publisher Copyright:
© 2021, The Author(s).

Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.

Biologic refractory disease in axial spondyloarthritis - Definition, prevalence and patient characteristics. A collaboration between five Nordic biologic registries

Giuseppe, DD., Lindström, U., Aaltonen, K., Relas, H., Provan, SA., Gudbjornsson, B., Hetland, M. L., Askling, J., Jørgensen, T. S., Dreyer, L., Nordström, D., Michelsen, B., Geirsson, AJ., Jacobsson, LTH. & Glintborg, B., 2021, I: Annals of the Rheumatic Diseases. 80, Supplement 1, s. 82-3 2 s., OP0140.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

Originalsprog Engelsk
Artikelnummer OP0140
Tidsskrift Annals of the Rheumatic Diseases
Vol/bind 80
Udgave nummer Supplement 1
Sider (fra-til) 82-3
Antal sider 2
ISSN 0003-4967
Status Udgivet - 2021

Biopsychosocial Rehabilitation for Inflammatory Arthritis and Osteoarthritis Patients: A systematic review and meta-analysis of randomized trials

Pedersen, M. B., Thinggaard, P., Geenen, R., Rasmussen, M. U., De Wit, M., March, L., Mease, P., Choy, E., Conaghan, P. G., Simon, L., Hansen, A. F., Tarp, S., Schiøttz-Christensen, B., Juhl, C. B., Nielsen, S. M., Amris, K. & Christensen, R., 8 nov. 2021, (E-pub ahead of print) I: Arthritis Care & Research.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

OBJECTIVE: To assess the benefits and harms associated with biopsychosocial rehabilitation in patients with inflammatory arthritis and osteoarthritis (OA).

METHODS: We performed a systematic review and meta-analysis. Data were collected through electronic searches of Cochrane CENTRAL, MEDLINE, Embase, PsycInfo, and CINAHL databases up to March 2019. Trials examining the effect of biopsychosocial rehabilitation in adults with inflammatory arthritis and/or OA were considered eligible, excluding rehabilitation adjunct to surgery. The primary outcome for benefit was pain and total withdrawals for harm.

RESULTS: Of the 27 trials meeting the eligibility criteria, 22 trials (3,750 participants) reported sufficient data to be included in the quantitative synthesis. For patient-reported outcome measures, biopsychosocial rehabilitation was slightly superior to control for pain relief (standardized mean difference [SMD] -0.19 [95% confidence interval (95% CI) -0.31, -0.07]), had a small effect on patient global assessment score (SMD -0.13 [95% CI -0.26, -0.00]), with no apparent effect on health-related quality of life, fatigue, self-reported disability/physical function, mental well-being, and reduction in pain intensity ≥30%. Clinician-measured outcomes displayed a small effect on observed disability/physical function (SMD -0.34 [95% CI -0.57, -0.10]), a large effect on physician global assessment score (SMD -0.72 [95% CI -1.18, -0.26]), and no effect on inflammation. No difference in harms existed in terms of the number of withdrawals, adverse events, or serious adverse events.

CONCLUSION: Biopsychosocial rehabilitation produces a significant but clinically small beneficial effect on patient-reported pain among patients with inflammatory arthritis and OA, with no difference in harm. Methodologic weaknesses were observed in the included trials, suggesting low-to-moderate confidence in the estimates of effect.

Originalsprog Engelsk
Tidsskrift Arthritis Care & Research
ISSN 2151-464X
DOI
Status E-pub ahead of print - 8 nov. 2021

Bibliografisk note

This article is protected by copyright. All rights reserved.

Biopsychosocial rehabilitation for inflammatory arthritis and osteoarthritis: A systematic review and meta-analysis of randomized trials

Pedersen, M. B., Thinggaard, P., Geenen, R., Rasmussen, M. U., De Wit, M., March, L., Mease, P., Choy, E., Conaghan, P. G., Simon, L., Hansen, A. F., Tarp, S., Schiøttz-Christensen, B., Juhl, C. B., Nielsen, S. M., Amris, K. & Christensen, R., 8 nov. 2021, (E-pub ahead of print) I: Arthritis Care & Research.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

OBJECTIVE: To assess the benefits and harms associated with biopsychosocial rehabilitation in patients with inflammatory arthritis and osteoarthritis (OA).

METHODS: We performed a systematic review and meta-analysis. Data were collected through electronic searches of Cochrane CENTRAL, MEDLINE, Embase, PsycInfo, and CINAHL databases up to March 2019. Trials examining the effect of biopsychosocial rehabilitation in adults with inflammatory arthritis and/or OA were considered eligible, excluding rehabilitation adjunct to surgery. The primary outcome for benefit was pain and total withdrawals for harm.

RESULTS: Of the 27 trials meeting the eligibility criteria, 22 trials (3,750 participants) reported sufficient data to be included in the quantitative synthesis. For patient-reported outcome measures, biopsychosocial rehabilitation was slightly superior to control for pain relief (standardized mean difference [SMD] -0.19 [95% confidence interval (95% CI) -0.31, -0.07]), had a small effect on patient global assessment score (SMD -0.13 [95% CI -0.26, -0.00]), with no apparent effect on health-related quality of life, fatigue, self-reported disability/physical function, mental well-being, and reduction in pain intensity ≥30%. Clinician-measured outcomes displayed a small effect on observed disability/physical function (SMD -0.34 [95% CI -0.57, -0.10]), a large effect on physician global assessment score (SMD -0.72 [95% CI -1.18, -0.26]), and no effect on inflammation. No difference in harms existed in terms of the number of withdrawals, adverse events, or serious adverse events.

CONCLUSION: Biopsychosocial rehabilitation produces a significant but clinically small beneficial effect on patient-reported pain among patients with inflammatory arthritis and OA, with no difference in harm. Methodologic weaknesses were observed in the included trials, suggesting low-to-moderate confidence in the estimates of effect.

Originalsprog Engelsk
Tidsskrift Arthritis Care & Research
ISSN 2151-464X
DOI
Status E-pub ahead of print - 8 nov. 2021

Bibliografisk note

This article is protected by copyright. All rights reserved.

Biosimilar to biosimilar infliximab switching in real-world patients with inflammatory arthritis followed in the Danish DANBIO registry: Switch from originator infliximab to CT-P13 and then to GP1111

Nabi, H., Glintborg, B., Loft, AG., Hendricks, O., Pedersen, JK., Just, SA., Ahmed, R., Danebod, K., Munk, H., Colic, A., Linauskas, A., Jensen, D. V., Raun, J., Grydehøj, J., Christensen, LB., Manilo, N., Lomborg, N., Kristensen, S., Mehnert, F., Krogh, NS., & 1 flereHetland, M. L., 2021, I: Arthritis and Rheumatology. 73, No. S9, s. 1161-3 3 s., 0573.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

Originalsprog Engelsk
Artikelnummer 0573
Tidsskrift Arthritis and Rheumatology
Vol/bind 73
Udgave nummer No. S9
Sider (fra-til) 1161-3
Antal sider 3
ISSN 2326-5191
Status Udgivet - 2021

Bladder Cancer Nursing Updates (EAUN BC SIG and ANZUP BC SIG): Global Updates and Future Joint Directions

Schubach, K., Diocera, M. & Lauridsen, S. V., feb. 2021, I: Seminars in Oncology Nursing. 37, 1, 151115.

Publikation: Bidrag til tidsskriftReviewpeer review

Originalsprog Engelsk
Artikelnummer 151115
Tidsskrift Seminars in Oncology Nursing
Vol/bind 37
Udgave nummer 1
ISSN 0749-2081
DOI
Status Udgivet - feb. 2021

Breast cancer rate after oophorectomy: A Prospective Danish Cohort Study

Koch, T., Jørgensen, J. T., Christensen, J., Dehlendorff, C., Priskorn, L., Simonsen, M. K., Duun-Henriksen, A. K., Andersen, Z. J., Juul, A., Bräuner, E. V. & Hickey, M., 1 aug. 2021, I: International Journal of Cancer. 149, 3, s. 585-593 9 s.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

The association between oophorectomy and risk of breast cancer in the general population is uncertain. The aim of our study was to determine the breast cancer rate in women from the general population after oophorectomy (performed before/after menopause), and whether this varies by use of hormone replacement therapy (HRT), hysterectomy, body mass index (BMI) and shift work. The study included 24 409 female nurses (aged ≥45 years) participating in the Danish Nurse Cohort. Nurses were followed from cohort entry until date of breast cancer, death, emigration or end of follow-up at 31 December 2018, whichever came first. Poisson regression with log-transformed person-years as the offset examined the association between oophorectomy and breast cancer (all ages and stratified by menopausal status at time of oophorectomy). The potential modifying effect of HRT use, hysterectomy, BMI and shift work on the associations was estimated. During 502 463 person-years of follow-up, 1975 (8.1%) nurses were diagnosed with breast cancer. Bilateral oophorectomy was associated with a reduced breast cancer rate compared to nurses with preserved ovaries, adjusted rate ratio (95% confidence interval): 0.79 (0.64; 0.99). Similar associations (magnitude and direction) were detected for unilateral oophorectomy and when stratifying according to menopausal status at time of oophorectomy, but without statistical significance. Unilateral and bilateral oophorectomy is associated with a reduced breast cancer rate in women from the general population. This association is not modified by use of HRT, hysterectomy, BMI or shift work.

Originalsprog Engelsk
Tidsskrift International Journal of Cancer
Vol/bind 149
Udgave nummer 3
Sider (fra-til) 585-593
Antal sider 9
ISSN 0020-7136
DOI
Status Udgivet - 1 aug. 2021

Change in psoriatic arthritis outcome measures impacts SF-36 physical and mental component scores differently: an observational cohort study

Skougaard, M., Jørgensen, T. S., Jensen, M. J., Ballegaard, C., Guldberg-Møller, J., Egeberg, A., Christensen, R., Benzin, P., Stisen, Z. R., Merola, J. F., Coates, L. C., Strand, V., Mease, P. & Kristensen, L. E., 2021, I: Rheumatology Advances in Practice. 5, 3, s. rkab076 rkab076.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Objective: The objective was to investigate interplay and physical and mental component scores between change (Δ) in health-related quality of life (HRQoL) quantified by the physical component score (PCS) and mental component score (MCS) retrieved from short-form health survey (SF-36), change in disease activity (ΔDAS28CRP) and manifestations of PsA.

Methods: PsA patients initiating new medical therapy were enrolled. Independent disease measures evaluating disease activity, enthesitis, psoriasis, pain and fatigue were collected at treatment initiation and after 4 months. Interplay between independent disease measures and dependent outcome measures, ΔPCS and ΔMCS, was described with univariate regression analyses. Multivariate regression analyses were applied to assess the impact of independent variables, such as individual disease outcome measures vs ΔDAS28CRP on ΔPCS and ΔMCS.

Results: One hundred and eight PsA patients were included. In the univariate regression analyses, improvement in fatigue, pain and disability were associated with improvement in ΔPCS (β; -2.08, -0.18 and -13.00, respectively; all P < 0.001) and ΔMCS (β; -1.59, -0.12 and -6.07, respectively; P < 0.001, P < 0.001 and P = 0.003, respectively). When patient-reported outcomes were included in the final multivariate models, improvements in ΔPCS and ΔMCS were associated with improvements in pain, fatigue and disability (P < 0.001). Improvement in enthesitis impacted ΔPCS positively (β -0.31, P < 0.001). No association was found between change in skin psoriasis, ΔPCS and ΔMCS (β 0.15, P = 0.056 and β 0.05, P = 0.561, respectively).

Conclusion: In this PsA patient cohort, diminishing pain, disability and fatigue improved PCS and MCS significantly. Changes in enthesitis and psoriasis did not grossly impact HRQoL compared with DAS28CRP. Individual PsA manifestations influence HRQoL differently, which is important clinically when targeting treatment.

Trial registration: ClinicalTrials.gov, http://clinicaltrials.gov, NCT02572700.

Originalsprog Engelsk
Artikelnummer rkab076
Tidsskrift Rheumatology Advances in Practice
Vol/bind 5
Udgave nummer 3
Sider (fra-til) rkab076
ISSN 2514-1775
DOI
Status Udgivet - 2021

Bibliografisk note

© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology.

Unintended negative outcomes on child behavior due to lockdown and home confinement following the corona virus disease (COVID-19) pandemic needs highlighting to effectively address these issues in the current and future health crises. In this sub-study of the ODIN-study, the objectives were to determine whether the Danish lockdown and home confinement following the COVID-19 pandemic affected changes in emotional-behavioral functioning of pre-school-aged children using the validated Strength and Difficulties Questionnaire (SDQ) answered by parents shortly before lockdown and 3 weeks into lockdown, and moreover, to examine whether baseline family and social characteristics could predict change in child emotional-behavioral functioning during lockdown. Parents of 40 (82%) children with a mean(SD) age of 5.0(0.7) completed the baseline questionnaire and the lockdown follow-up questionnaire. The SDQ-Total difficulties score (SDQ-TD) and Prosocial Behavioral score (PSB) changed significantly from pre- to lockdown [SDQ-TD mean(SD): 6.0(3.8) and 7.9(5.2); P = 0.02, respectively and PSB mean(SD): 8.5(1.4) and 7.9(1.5); P = 0.03, respectively]. Attending leisure time activities before lockdown was a predicting factor of changes to the worse in the children's SDQ-TD scores, with a mean difference in SDQ-TD between those with and without activities of 3.16 (95%CI 0.27-6.12); P = 0.03. In conclusion, the study showed a modest decrease in child-emotional behavioral functioning during the COVID-19 lockdown, potentially due to parental stress. Although these results might not be generalizable due to small sample size and selected population, the results point to a need of a greater awareness of child mental wellbeing during a lockdown situation.

Originalsprog Engelsk
Artikelnummer 643057
Tidsskrift Frontiers in Psychology
Vol/bind 12
Sider (fra-til) 643057
ISSN 1664-1078
DOI
Status Udgivet - 31 maj 2021

INTRODUCTION: Patients addicted to alcohol or drug often have additional unhealthy lifestyles, adding to the high mortality and morbidity in this patient group. Therefore, it is important to consider lifestyle interventions as part of the usual addiction treatment.

OBJECTIVE: The aim was to identify predictors of successful changes in lifestyle risk factors among patients in treatment for alcohol or drug addiction.

METHODS: We conducted a secondary analysis of a trial using a 6-week intensive integrated lifestyle intervention: The very integrated program (VIP). Patients were recruited in Addiction Centres Malmö and Psychiatry Skåne, Sweden. The primary outcome was successful changes in lifestyle, measured as quitting tobacco, exercising 30 min per day, and not being over- or underweight after 6 weeks and 12 months.

RESULTS: A total of 212 patients were included in the RCT, and 128 were included in this secondary analysis: 108 at 6 weeks and 89 at 12 months of follow-up. A total of 69 patients were respondents at both follow-ups. The follow-up rates were 51 and 42%, respectively. More education, having at least 2 lifestyle risk factors and having a high quality of life were predictors of a successful change in lifestyle after 6 weeks. After 12 months, the predictors for a successful outcome were having 3 or more risk factors, while an education level up to 3 years was a negative predictor.

CONCLUSIONS: Having several unhealthy lifestyles in addition to alcohol and drug addiction was a significant predictor of successful lifestyle changes in the short- and long term after the VIP for lifestyle interventions. Likewise, education was significant. The results should be considered in future development and research among this vulnerable group of patients.

Originalsprog Engelsk
Tidsskrift European addiction research
Vol/bind 27
Udgave nummer 2
Sider (fra-til) 123-130
Antal sider 8
ISSN 1022-6877
DOI
Status Udgivet - mar. 2021

Chronic Pain and Assessment of Pain Sensitivity in Patients With Axial Spondyloarthritis: Results From the SPARTAKUS Cohort

Mogard, E., Olofsson, T., Bergman, S., Bremander, A., Kristensen, L. E., Olsen, J. K., Wallman, J. K. & Lindqvist, E., nov. 2021, I: Journal of Rheumatology. 48, 11, s. 1672-1679 8 s.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

OBJECTIVE: To study differences in pain reports between patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (nr-axSpA), and to assess how pain sensitivity measures associate with disease and health outcomes.

METHODS: Consecutive patients with axial SpA (axSpA) were enrolled in the population-based SPARTAKUS cohort (2015-2017) and classified as AS (n = 120) or nr-axSpA (n = 55). Pain was assessed with questionnaires (intensity/duration/distribution) and computerized cuff pressure algometry to measure pain sensitivity (pain threshold/pain tolerance/temporal summation of pain). Linear regression models were used to compare pain measures between patients with AS and nr-axSpA, and to assess associations between pain sensitivity measures and disease and health outcomes.

RESULTS: Of 175 patients with axSpA, 43% reported chronic widespread pain, with no significant differences in any questionnaire-derived or algometry-assessed pain measures between patients with AS and nr-axSpA. Lower pain tolerance was associated with longer symptom duration, worse Ankylosing Spondylitis Disease Activity Score using C-reactive protein (ASDAS-CRP), Bath Ankylosing Spondylitis Functional Index, and Bath Ankylosing Spondylitis Metrology Index (BASMI), more pain regions, unacceptable pain, worse Maastricht AS Enthesitis Score (MASES), fatigue, anxiety, and health-related quality of life. Further, lower pain threshold was associated with worse ASDAS-CRP and MASES, whereas higher temporal summation was associated with longer symptom duration, unacceptable pain, and worse BASMI.

CONCLUSION: Chronic pain is common in axSpA, with no observed differences in any pain measures between patients with AS and nr-axSpA. Further, higher pain sensitivity is associated with having worse disease and health outcomes. The results indicate that patients with AS and nr-axSpA, in line with most clinical characteristics, have a similar pain burden, and they highlight large unmet needs regarding individualized pain management, regardless of axSpA subgroup.

Originalsprog Engelsk
Tidsskrift Journal of Rheumatology
Vol/bind 48
Udgave nummer 11
Sider (fra-til) 1672-1679
Antal sider 8
ISSN 0315-162X
DOI
Status Udgivet - nov. 2021

Bibliografisk note

Copyright © 2021 by the Journal of Rheumatology.

Chronic Sequelae After Muscle Strain Injuries: Influence of Heavy Resistance Training on Functional and Structural Characteristics in a Randomized Controlled Trial

Bayer, M. L., Hoegberget-Kalisz, M., Svensson, R. B., Hjortshoej, M. H., Olesen, J. L., Nybing, J. D., Boesen, M., Magnusson, S. P. & Kjaer, M., aug. 2021, I: The American journal of sports medicine. 49, 10, s. 2783-2794 12 s.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

BACKGROUND: Muscle strain injury leads to a high risk of recurrent injury in sports and can cause long-term symptoms such as weakness and pain. Scar tissue formation after strain injuries has been described, yet what ultrastructural changes might occur in the chronic phase of this injury have not. It is also unknown if persistent symptoms and morphological abnormalities of the tissue can be mitigated by strength training.

PURPOSE: To investigate if heavy resistance training improves symptoms and structural abnormalities after strain injuries.

STUDY DESIGN: Randomized controlled trial; Level of evidence, 1.

METHODS: A total of 30 participants with long-term weakness and/or pain after a strain injury of the thigh or calf muscles were randomized to eccentric heavy resistance training of the injured region or control exercises of the back and abdominal muscle. Isokinetic (hamstring) or isometric (calf) muscle strength was determined, muscle cross-sectional area measured, and pain and function evaluated. Scar tissue ultrastructure was determined from biopsy specimens taken from the injured area before and after the training intervention.

RESULTS: Heavy resistance training over 3 months improved pain and function, normalized muscle strength deficits, and increased muscle cross-sectional area in the previously injured region. No systematic effect of training was found upon pathologic infiltration of fat and blood vessels into the previously injured area. Control exercises had no effect on strength, cross-sectional area, or scar tissue but a positive effect on patient-related outcome measures, such as pain and functional scores.

CONCLUSION: Short-term strength training can improve sequelae symptoms and optimize muscle function even many years after a strain injury, but it does not seem to influence the overall structural abnormalities of the area with scar tissue.

REGISTRATION: NCT02152098 (ClinicalTrials.gov identifier).

Originalsprog Engelsk
Tidsskrift The American journal of sports medicine
Vol/bind 49
Udgave nummer 10
Sider (fra-til) 2783-2794
Antal sider 12
ISSN 0363-5465
DOI
Status Udgivet - aug. 2021

Commentary: Future Directions in Bladder Cancer Care

Jensen, B. T. & Lauridsen, S. V., feb. 2021, I: Seminars in Oncology Nursing. 37, 1, 151117.

Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

Originalsprog Engelsk
Artikelnummer 151117
Tidsskrift Seminars in Oncology Nursing
Vol/bind 37
Udgave nummer 1
ISSN 0749-2081
DOI
Status Udgivet - feb. 2021
Originalsprog Engelsk
Udgivelsessted København
Forlag University of Copenhagen
Status Udgivet - 14 jan. 2021

OBJECTIVES: To explore the prognostic value of pre-specified comorbidities on treatment outcomes in PsA, and to compare baseline data with cutaneous psoriasis without arthritis and healthy controls (HC).

METHODS: Patients initiating conventional synthetic/biological disease-modifying antirheumatic drugs were enrolled in this clinical observational cohort study, and data on comorbidities, and clinical and patient-reported outcomes were retrieved at baseline and after 4 months. Pearson's chi-squared tests were performed to investigate the prognostic value of pre-specified comorbidities and achievement of ACR20, DAPSA50 and MDA. Mann-Whitney U tests were used to compare OMERACT PsA Core Outcome Set (COS) measures at baseline and follow-up for the pre-specified comorbidities.

RESULTS: A total of 100 PsA patients were included at baseline. Statistically significantly fewer patients with obesity achieved DAPSA50 compared with patients without obesity (P =0.035), and fewer patients with hypertension (P =0.034) and Charlson Comorbidity Index (CCI) ≥1 (P =0.027), respectively, achieved MDA compared with patients without these comorbidities. Patients with obesity, hypertension, widespread pain, and CCI ≥1 had significantly worse COS measures at follow-up compared with patients without these comorbidities. At baseline, patients with PsA had higher disease burden compared with patients with cutaneous psoriasis and HC, including higher pain (P <0.001) and fatigue (P <0.001) scores, and more widespread pain (P =0.002).

CONCLUSION: Obesity, hypertension and CCI ≥1 were prognostic factors for poorer treatment outcome rates in PsA. Pain and fatigue were more frequently reported among patients with PsA compared with patients with cutaneous psoriasis and HC.

TRIAL REGISTRATION: The Danish National Committee on Health Research Ethics: H-15009080; Data Protection Agency: 2012-58-0004; ClinicalTrials.gov: NCT02572700.

Originalsprog Engelsk
Tidsskrift Rheumatology (Oxford, England)
Vol/bind 60
Udgave nummer 7
Sider (fra-til) 3289-3300
Antal sider 12
ISSN 1462-0324
DOI
Status Udgivet - 1 jul. 2021

Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial

Nabi, H., Georgiadis, S., Loft, A. G., Hendricks, O., Jensen, D. V., Andersen, M., Chrysidis, S., Colic, A., Danebod, K., Hussein, M. R., Kalisz, M. H., Kristensen, S., Lomborg, N., Manilo, N., Munk, H. L., Pedersen, J. K., Raun, J. L., Mehnert, F., Krogh, N. S., Hetland, M. L., & 1 flereGlintborg, B., nov. 2021, I: Annals of the Rheumatic Diseases. 80, 11, s. 1400-1409 10 s.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

OBJECTIVES: In 2018, a nationwide mandatory switch from originator to biosimilar adalimumab was conducted in Denmark. The available biosimilar was GP2017 (Hyrimoz) in Eastern regions and SB5 (Imraldi) in Western regions. We aimed to assess the comparative effectiveness of GP2017 versus SB5 in patients with rheumatoid arthritis (RA)/psoriatic arthritis (PsA)/axial spondyloarthritis (AxSpA).

METHODS: Observational cohort study based on the DANBIO registry with geographical cluster pseudo-randomisation, analysed by emulating a randomised clinical trial. Main outcome was adjusted 1-year treatment retention (Cox regression). Furthermore, 6 months' remission rates (logistic regression), reasons for withdrawal and back-switching to originator were investigated (overall and stratified by indication).

RESULTS: Overall, of 1570 eligible patients, 1318 switched and were included (467 RA/321 PsA/530 AxSpA); 623 (47%) switched to GP2017, 695 (53%) to SB5. Baseline characteristics of the two clusters were largely similar, but some differences in registration practice were observed. The combined 1-year retention rate for the two biosimilars was 89.5%. Compared with SB5, estimated risk of withdrawal for GP2017 was lower (HR 0.60; 95% CI 0.42 to 0.86) and 6 months' remission rate was higher (OR 1.72; 95% CI 1.25 to 2.37). Stratified analyses gave similar results (statistically significant for RA). During 1 year, 8.5% and 12.9% withdrew GP2017 and SB5, respectively (primarily lack of effect and adverse events), of whom 48 patients (3.6%) back-switched.

CONCLUSION: This head-to-head comparison of GP2017 versus SB5 following a mandatory switch from the originator indicated differences in effectiveness in routine care. This may reflect a true difference, but other explanations, for example, differences in excipients, differences between clusters and residual confounding cannot be ruled out.

Originalsprog Engelsk
Tidsskrift Annals of the Rheumatic Diseases
Vol/bind 80
Udgave nummer 11
Sider (fra-til) 1400-1409
Antal sider 10
ISSN 0003-4967
DOI
Status Udgivet - nov. 2021

Bibliografisk note

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Comparing Two Independent Populations Using a Test Based on Empirical Likelihood and Trimmed Means

Delesa-Vēliņa, M., Valeinis, J. & Luta, G., apr. 2021, I: Lithuanian Mathematical Journal. 61, 2, s. 199-216 18 s.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

We develop a new robust empirical likelihood-based test for comparing the trimmed means of two independent populations. The simulation results indicate that the test has asymptotically correct level under various data distributions and controls the Type I error adequately for medium-size samples. For nonnormal data distributions, the power of the test is comparable to robust alternatives like Yuen’s test for the trimmed means and considerably exceeds that of the tests based on the means. In small sample settings the test version for the difference of 10% trimmed means exhibits robustness to the combined presence of nonnormality and heterogeneity.

Originalsprog Engelsk
Tidsskrift Lithuanian Mathematical Journal
Vol/bind 61
Udgave nummer 2
Sider (fra-til) 199-216
Antal sider 18
ISSN 0363-1672
DOI
Status Udgivet - apr. 2021

Bibliografisk note

Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis

Lindström, U., Glintborg, B., Di Giuseppe, D., Schjødt Jørgensen, T., Gudbjornsson, B., Lederballe Grøn, K., Aarrestad Provan, S., Michelsen, B., Lund Hetland, M., Wallman, J. K., Nordström, D., Trokovic, N., Love, T. J., Krogh, N. S., Askling, J., Jacobsson, L. T. H. & Kristensen, L. E., 2 aug. 2021, I: Rheumatology (Oxford, England). 60, 8, s. 3635-3645 11 s.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

OBJECTIVES: To compare treatment retention and response to secukinumab vs adalimumab, including the other four TNF inhibitors (TNFi) as comparators, in PsA.

METHODS: All patients with PsA starting secukinumab or a TNFi in 2015-2018 were identified in the biologic registers of the Nordic countries. Data on comorbidities were linked from national registers. One-year treatment retention and hazard ratios (HRs) for treatment discontinuation were calculated. The proportion achieving a 6 month 28-joint Disease Activity Index for Psoriatic Arthritis (DAPSA28) remission was determined together with odds ratios (ORs) for remission (logistic regression). Both HRs and ORs were calculated with adalimumab as the reference and adjusted for baseline characteristics and concurrent comorbidities. All analyses were stratified by the line of biologic treatment (first, second, third+).

RESULTS: We identified 6143 patients contributing 8307 treatment courses (secukinumab, 1227; adalimumab, 1367). Secukinumab was rarely used as the first biologic, otherwise baseline characteristics were similar. No clinically significant differences in treatment retention or response rates were observed for secukinumab vs adalimumab. The adjusted HRs for discontinuation per the first, second and third line of treatment were 0.98 (95% CI 0.68, 1.41), 0.94 (0.70, 1.26) and 1.07 (0.84, 1.36), respectively. The ORs for DAPSA28 remission in the first, second and third line of treatment were 0.62 (95% CI 0.30, 1.28), 0.85 (0.41, 1.78) and 0.74 (0.36, 1.51), respectively. In the subset of patients previously failing a TNFi due to ineffectiveness, the results were similar.

CONCLUSION: No significant differences in treatment retention or response were observed between secukinumab and adalimumab, regardless of the line of treatment. This suggests that even in patients who have failed a TNFi, choosing either another TNFi or secukinumab may be equally effective.

Originalsprog Engelsk
Tidsskrift Rheumatology (Oxford, England)
Vol/bind 60
Udgave nummer 8
Sider (fra-til) 3635-3645
Antal sider 11
ISSN 1462-0324
DOI
Status Udgivet - 2 aug. 2021

Concurrent Validity Between Electronically Administered Physical Activity Questionnaires and Objectively Measured Physical Activity in Danish Community-Dwelling Older Adults

Larsen, R. T., Korfitsen, C. B., Juhl, C. B., Boje Andersen, H., Langberg, H. & Christensen, J., aug. 2021, I: Journal of Aging and Physical Activity. 29, 4, s. 595-603 9 s.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

AIM: To investigate the concurrent validity of the International Physical Activity Questionnaire-short form (IPAQ-SF) and the Nordic Physical Activity Questionnaire-short (NPAQ-short) when compared with objectively measured daily steps among older adults.

METHODS: Spearman's ρ between IPAQ-SF and NPAQ-short and objectively measured steps using Garmin Vivofit 3 physical activity monitors.

RESULTS: A total of 54 participants were included. The IPAQ-SF subscales' moderate physical activity (PA), moderate to vigorous PA (MVPA), and sedentary time showed little or no correlation with daily steps. The NPAQ-short subscales' vigorous PA, moderate PA, and MVPA showed little or no correlation. The IPAQ-SF subscales' vigorous PA and walking showed fair correlation. Only the IPAQ-SF metabolic equivalent of task minutes showed moderate to good correlation with daily steps. The IPAQ-SF categories and NPAQ-short categorization of World Health Organization compliance were significantly different, but the magnitudes were small and distributions indicated problems with the categorization.

CONCLUSION: The concurrent validity is low, as the scores did not reflect objectively measured daily steps.

Originalsprog Engelsk
Tidsskrift Journal of Aging and Physical Activity
Vol/bind 29
Udgave nummer 4
Sider (fra-til) 595-603
Antal sider 9
ISSN 1063-8652
DOI
Status Udgivet - aug. 2021

Pages